Un único enfoque terapéutico basado en ARN contra múltiples tipos de virus de ARN

A groundbreaking study has revealed a potential universal treatment for a wide range of RNA viruses, offering hope in the face of persistent challenges posed by rapidly mutating pathogens. Researchers at National Taiwan University discovered a novel method using an engineered mitochondrial enzyme called MOM-ENDOG, which effectively targets and degrades viral RNA without damaging host cell DNA. This discovery could lead to a new class of broad-spectrum antiviral drugs capable of combating multiple RNA viruses, including those responsible for diseases such as influenza, dengue, and Zika. The researchers identified that RNA viruses synthesize their genetic material within structures known as Mito/ER spheres found inside infected cells. During this process, a mitochondrial enzyme named ENDOG leaks into the cytoplasm, where it acts as an antiviral agent by breaking down viral RNA. However, this same enzyme can also move into the nucleus, potentially causing damage to the host’s DNA. To address this issue, scientists developed a modified version of ENDOG, termed MOM-ENDOG, which is specifically anchored to the mitochondrial surface. This modification allows MOM-ENDOG to target and destroy viral RNA without entering the nucleus, thus avoiding harmful side effects. In experiments conducted by the team, delivery of modified mRNA encoding MOM-ENDOG significantly reduced the replication of several RNA viruses, including vesicular stomatitis virus (VSV), influenza, dengue, and Zika. The effectiveness of MOM-ENDOG was confirmed through extensive testing, demonstrating its ability to neutralize these diverse viruses despite their varying genetic makeup and mutation rates. According to Zee-Fen Chang, chair professor at the Center of Nucleic Acid Medicine, National Taiwan University College of Medicine, this approach represents a major advancement in antiviral therapy due to its resistance to viral mutations. The study, published in Nature Communications, outlines the detailed mechanisms behind MOM-ENDOG’s functionality. By anchoring ENDOG to the mitochondrial membrane, the researchers ensured that the enzyme remained localized to the site of viral RNA synthesis, thereby enhancing its efficacy while minimizing potential harm to the host cell. This targeted strategy not only improves the specificity of the therapeutic intervention but also reduces the likelihood of unintended consequences associated with traditional antiviral treatments. The implications of this research extend beyond individual viral infections, suggesting a versatile platform for developing therapies against future RNA viruses. Given the increasing threat of emerging infectious diseases, the ability to create a single therapeutic solution that addresses multiple viral threats simultaneously holds immense promise for global public health. The findings underscore the importance of understanding the intricate interplay between viral replication and cellular processes, paving the way for innovative approaches in virology and pharmacology. The research team continues to explore the clinical applications of MOM-ENDOG, aiming to translate these laboratory findings into practical medical solutions. Ongoing studies will focus on evaluating the safety and efficacy of MOM-ENDOG in preclinical models before advancing to human trials. As the scientific community awaits further developments, the potential impact of this breakthrough on the treatment of RNA viral infections remains a topic of intense interest and optimism.